AR031978A1 - Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion - Google Patents

Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion

Info

Publication number
AR031978A1
AR031978A1 ARP000104841A ARP000104841A AR031978A1 AR 031978 A1 AR031978 A1 AR 031978A1 AR P000104841 A ARP000104841 A AR P000104841A AR P000104841 A ARP000104841 A AR P000104841A AR 031978 A1 AR031978 A1 AR 031978A1
Authority
AR
Argentina
Prior art keywords
reboxetine
dosage form
manufacture
composition
time
Prior art date
Application number
ARP000104841A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR031978A1 publication Critical patent/AR031978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una forma de dosificacion de liberacion sostenida que es adaptada para la liberacion de reboxetina a un índice uniforme durante un período de tiempo prolongado; uso de una forma de dosificacion de liberacion sostenida adaptada para liberar reboxetina a un índice uniforme durante un período de tiempo prolongado que es para la manufactura de un medicamento para el tratamiento de una condicion en un sujeto que responde a reboxetina, y una composicion. Las formas de dosificacion de liberacion sostenida proporciona concentraciones de reboxetina de plasma de estado de firme promedio terapéuticamente efectivas cuando se administran una vez al día. Este régimen de dosificacion de una vez al día produce solo una ocurrencia de concentracion de reboxetina de plasma pico en cada período de 24 horas. Además la concentracion de reboxetina de plasma pico se produce en un momento posterior luego de la administracion de la dosis, y exhibe una magnitud menor que la concentracion de reboxetina de plasma pico que se produce luego de la administracion de reboxetina en una forma de dosificacion de liberacion inmediata. Se describe además una forma de dosificacion adaptada por el suministro sostenido de droga durante un período de tiempo prolongado que comprende reboxetina y un carbohidrato.
ARP000104841A 1999-09-15 2000-09-15 Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion AR031978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15399799P 1999-09-15 1999-09-15

Publications (1)

Publication Number Publication Date
AR031978A1 true AR031978A1 (es) 2003-10-22

Family

ID=22549601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104841A AR031978A1 (es) 1999-09-15 2000-09-15 Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion

Country Status (13)

Country Link
US (2) US6387403B1 (es)
EP (1) EP1216031B1 (es)
JP (1) JP2003509354A (es)
KR (2) KR100723850B1 (es)
AR (1) AR031978A1 (es)
AT (1) ATE356619T1 (es)
AU (1) AU7490700A (es)
CA (1) CA2384624C (es)
CO (1) CO5210862A1 (es)
DE (1) DE60033947T2 (es)
PE (1) PE20010625A1 (es)
TW (1) TWI233809B (es)
WO (1) WO2001019337A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
JP4717436B2 (ja) * 2002-04-29 2011-07-06 アルザ・コーポレーシヨン 不純物形成を減らすための、２級アミンを含む減少したギ酸ポリ（アルキレンオキシド）
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
ATE401866T1 (de) * 2003-02-11 2008-08-15 Alza Corp Verfahren und dosierformen mit modifizierter schichtgeometrie
CA2518734A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
MEP3608A (en) * 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
AU2006256851C1 (en) * 2005-06-09 2010-07-15 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8088786B2 (en) * 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US10485770B2 (en) * 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
EP2717813B1 (en) * 2011-06-06 2020-05-20 Auritec Pharmaceuticals Drug delivery device employing wicking release window
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
CN111077238A (zh) * 2019-11-12 2020-04-28 北京和合医学诊断技术股份有限公司 检测血液中瑞波西汀药物含量液相色谱分析方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
WO1995034582A1 (en) 1994-06-16 1995-12-21 Pharmacia S.P.A. Bioadhesive starches and process for their preparation
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
JP2001517628A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
EP0919234A3 (en) 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine

Also Published As

Publication number Publication date
US6387403B1 (en) 2002-05-14
KR20070007215A (ko) 2007-01-12
US6630165B2 (en) 2003-10-07
US20020146453A1 (en) 2002-10-10
EP1216031B1 (en) 2007-03-14
PE20010625A1 (es) 2001-06-04
CA2384624C (en) 2009-12-29
CO5210862A1 (es) 2002-10-30
DE60033947T2 (de) 2007-11-29
KR100831181B1 (ko) 2008-05-21
JP2003509354A (ja) 2003-03-11
WO2001019337A3 (en) 2001-08-09
TWI233809B (en) 2005-06-11
DE60033947D1 (de) 2007-04-26
KR100723850B1 (ko) 2007-05-31
ATE356619T1 (de) 2007-04-15
EP1216031A2 (en) 2002-06-26
AU7490700A (en) 2001-04-17
WO2001019337A2 (en) 2001-03-22
KR20020031424A (ko) 2002-05-01
CA2384624A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
AR031978A1 (es) Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion
AR040721A1 (es) Metodos y formas de dosificacion para l aliberacion controlada de paliperidona
UY27907A1 (es) Métodos y formas de dosificación para la liberación controlada de paliperidona
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
JP2005525329A5 (es)
JP2002540148A5 (es)
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
PT891186E (pt) Administração nasal de agentes para o tratamento de emese tardia
ECSP003661A (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia

Legal Events

Date Code Title Description
FC Refusal